JP2016501261A - マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用 - Google Patents

マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用 Download PDF

Info

Publication number
JP2016501261A
JP2016501261A JP2015546419A JP2015546419A JP2016501261A JP 2016501261 A JP2016501261 A JP 2016501261A JP 2015546419 A JP2015546419 A JP 2015546419A JP 2015546419 A JP2015546419 A JP 2015546419A JP 2016501261 A JP2016501261 A JP 2016501261A
Authority
JP
Japan
Prior art keywords
ppi
dendrimer
mal
iii
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015546419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501261A5 (cg-RX-API-DMAC10.html
Inventor
イダ・フラニアク−ピエトリガ
マリア・ブリシェフスカ
ディートマー・アッペルハンス
バルバラ・クライネルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Łódź
Original Assignee
University of Łódź
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Łódź filed Critical University of Łódź
Publication of JP2016501261A publication Critical patent/JP2016501261A/ja
Publication of JP2016501261A5 publication Critical patent/JP2016501261A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015546419A 2012-12-06 2013-12-06 マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用 Pending JP2016501261A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL401936A PL234888B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PLP-401936 2012-12-06
PCT/PL2013/000163 WO2014088435A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii

Publications (2)

Publication Number Publication Date
JP2016501261A true JP2016501261A (ja) 2016-01-18
JP2016501261A5 JP2016501261A5 (cg-RX-API-DMAC10.html) 2017-01-26

Family

ID=49955472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015546419A Pending JP2016501261A (ja) 2012-12-06 2013-12-06 マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用

Country Status (9)

Country Link
US (1) US9877985B2 (cg-RX-API-DMAC10.html)
EP (1) EP2928479A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501261A (cg-RX-API-DMAC10.html)
KR (1) KR20150093216A (cg-RX-API-DMAC10.html)
AU (1) AU2013356793A1 (cg-RX-API-DMAC10.html)
CA (1) CA2893973A1 (cg-RX-API-DMAC10.html)
IL (1) IL239144A0 (cg-RX-API-DMAC10.html)
PL (1) PL234888B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088435A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501260A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL416636A1 (pl) * 2016-03-24 2017-09-25 Univ Łódzki Medyczne zastosowanie dendrymeru polipropylenoiminowego czwartej generacji, opłaszczonego maltotriozą

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501260A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501260A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. JANASZEWSKA, NEW JOURNAL OF CHEMISTRY, vol. V36 N2, JPN5016000505, 1 January 2012 (2012-01-01), pages 428 - 437, ISSN: 0003754517 *
BARBARA ZIEMBA, BIOPOLYMERS, vol. V97 N8, JPN5016000507, 17 August 2012 (2012-08-17), pages 642 - 648, ISSN: 0003609151 *
BARBARA ZIEMBA: "INFLUENCE OF FOURTH GENERATION POLY (PROPYLENEIMINE) DENDRIMERS ON BLOOD CELLS", JOURNAL OF BIOMEDICAL METERIALS RESEARCH PART A, vol. V100A N11, JPN5016000506, 24 November 2012 (2012-11-24), pages 2870 - 2880, ISSN: 0003754518 *
FRANIAK-PIETRYGA IDA, BLOOD, vol. V120 N21, JPN5016000504, 16 November 2012 (2012-11-16), ISSN: 0003609148 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501260A (ja) * 2012-12-06 2016-01-18 ウニヴェルシテット・ウズキUniwersytet Lodzki マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用

Also Published As

Publication number Publication date
KR20150093216A (ko) 2015-08-17
AU2013356793A1 (en) 2015-07-23
PL234888B1 (pl) 2020-04-30
CA2893973A1 (en) 2014-06-12
WO2014088435A1 (en) 2014-06-12
PL401936A1 (pl) 2014-06-09
US20150306134A1 (en) 2015-10-29
EP2928479A1 (en) 2015-10-14
US9877985B2 (en) 2018-01-30
IL239144A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
Nooshabadi et al. Impact of atorvastatin loaded exosome as an anti-glioblastoma carrier to induce apoptosis of U87 cancer cells in 3D culture model
Gravelle et al. Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma
Franiak-Pietryga et al. The influence of maltotriose-modified poly (propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
Holwell et al. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
JP2025063161A (ja) ルテリアル、並びにその分離および培養方法
Lan et al. Exosomal microRNAs: an emerging important regulator in acute lung injury
Chen et al. Bufotalin loaded biomimetic nanodrug for combined chemo/photodynamic therapy of cancer
Pidala et al. Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial
Ünsal et al. The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro
Peng et al. Disrupting calcium homeostasis and glycometabolism in engineered lipid-based pharmaceuticals propel cancer immunogenic death
Benvenuto et al. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo
CN109745326B (zh) 一种包含吉非替尼和组蛋白去乙酰酶抑制剂的药物组合物,其脂质体制剂及其制药用途
KR20200055722A (ko) 약물 내성 신경아교종의 치료
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
Zhu et al. A hierarchically acidity-unlocking nanoSTING stimulant enables cascaded STING activation for potent innate and adaptive antitumor immunity
JP2016501260A (ja) マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用
EP2285420A2 (en) Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
Abdulmalek et al. Thymoquinone-conjugated liposomes improve cytotoxic and proapoptotic effects against hepatocellular cancer by altering the EGFR/ERK/MEK signaling axis
WO2020171138A1 (ja) 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
CN116785256A (zh) 一种可诱导细胞免疫性死亡的纳米颗粒材料及其制备方法和应用
Huang et al. Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles
RU2810558C1 (ru) Способ подбора лекарственных средств для реализации фармакологической индукции митохондриальной дисфункции в макрофагах для противоопухолевой терапии
WO2017163124A2 (en) Medical use of poly(propylene imine) glycodendrimers

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180313